Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Sakigake Status Should Not Be Granted to Novartis Products until It Takes Prevention Measures for Approval Delay: Pharma Bureau Chief
September 8, 2020
- Rakuten Medical’s Sakigake-Designated Photoimmunotherapy Clears MHLW Panel
September 8, 2020
- Medical Professionals to Be Prioritized in COVID-19 Vaccination: Govt Panel
September 8, 2020
- PMDA Reviewing Safety Risks for Takecab, 2 Other Drugs
September 7, 2020
- Former Pharma Bureau Chief Tarumi to Assume Vice Health Minister on September 14
September 7, 2020
- PMDA Presents Views on Efficacy, Safety Evaluations for Domestic Development of COVID-19 Vaccines
September 4, 2020
- Govt Holds 1st Meeting of Regenerative Medicine/Cell Therapy Panel, Eyeing Proposals in FY2021
September 4, 2020
- Will Temporary Measures in R&D Tax Credit System Be Extended? Enthusiasm for R&D Investment Could Determine Outcome
September 3, 2020
- MHLW Names 9 Candidates for Independent Safety Monitoring Panel for Pharma Products
September 3, 2020
- AMED Confirms 1st COVID-19 Case at HQ
September 3, 2020
- Japan Weighs COVAX Participation with Optional Purchase Arrangement
September 2, 2020
- AMED to Fund 7 More Company-Led COVID-19 Vaccine Projects Including Takeda, Daiichi Sankyo
September 2, 2020
- Japan Rolls Out Full-Fledged Sakigake System, Designations 2 Times a Year with Tougher Revocation Rules
September 1, 2020
- AMED to Focus on 5 Initiatives Including Strengthening Cooperation with Govt: New Chief
September 1, 2020
- Healthcare Spend Reaches Record 43.6 Trillion Yen in FY2019: MHLW
September 1, 2020
- MHLW Panel Roughly OKs Report on Stable API Supply Measures
August 31, 2020
- With Abe Hitting Exit, Industry Eyes Riveted on FY2021 Off-Year Re-Pricing Plan
August 31, 2020
- Japan in Talks to Secure 40 Million-Plus Doses of Moderna Vaccine via Takeda: Minister
August 31, 2020
- MHLW Set to Address API, Coronavirus Vaccine Issues in FY2021 Budget
August 28, 2020
- Japan’s 1st Topical Axillary Hyperhidrosis Drug, JT’s HIF-PH Inhibitor Now in Line for September Approval
August 28, 2020
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…